 <h1>Edoxaban Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>More frequently reported side effects include:</b> hemorrhage.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to edoxaban: oral tablet</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet)</p><p>Reduced Efficacy in Nonvalvular Atrial Fibrillation Patients with a Creatinine Clearance (CrCl) Greater than 95 mL/minute; Premature Discontinuation of Edoxaban Increases the Risk of Ischemic Events; Spinal/Epidural HematomaReduced Efficacy in Nonvalvular Atrial Fibrillation Patients with CrCl greater than 95 mL/min: Edoxaban should not be used in patients with CrCl greater than 95 mL/min. In the ENGAGE AF-TIMI 48 study, nonvalvular atrial fibrillation patients with CrCl greater than 95 mL/min had an increased rate of ischemic stroke with edoxaban 60 mg once daily compared to patients treated with warfarin. In these patients another anticoagulant should be used.Premature Discontinuation of Edoxaban Increases the Risk of Ischemic Events: Premature discontinuation of any oral anticoagulant in the absence of adequate alternative anticoagulation increases the risk of ischemic events. If edoxaban is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant as described in the transition guidance.Spinal/Epidural Hematoma: Epidural or spinal hematomas may occur in patients treated with edoxaban who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, edoxaban may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking edoxaban:</p><p>
<i>More common</i>
</p><ul>
<li>Bloody nose</li>
<li>heavy non-menstrual vaginal bleeding</li>
<li>pale skin</li>
<li>troubled breathing with exertion</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Bloody or black, tarry stools</li>
<li>vomiting of blood or material that looks like coffee grounds</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Confusion</li>
<li>cough</li>
<li>difficulty with speaking</li>
<li>double vision</li>
<li>fever</li>
<li>headache, sudden, severe</li>
<li>inability to move the arms, legs, or facial muscles</li>
<li>inability to speak</li>
<li>nausea</li>
<li>slow speech</li>
<li>vomiting</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Back pain</li>
<li>bleeding gums</li>
<li>blood in urine</li>
<li>burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings</li>
<li>fast heartbeat</li>
<li>hives, itching, rash, redness of the skin</li>
<li>hoarseness</li>
<li>irritation</li>
<li>joint pain, stiffness or swelling</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, sex organs</li>
<li>leg weakness</li>
<li>loss of bladder or bowel control</li>
<li>paralysis</li>
<li>pinpoint red spots on the skin</li>
<li>stomach pain</li>
<li>swelling of the eyelids, face, lips, hands, or feet</li>
<li>tightness in the chest</li>
<li>troubled breathing or swallowing</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of edoxaban may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Dizziness</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to edoxaban: oral tablet</i></p><h3>General</h3><p>During nonvalvular atrial fibrillation treatment, the most common adverse reactions were bleeding and anemia.  During deep venous thromboembolism and pulmonary embolism treatment, the most common adverse reactions were bleeding, rash, abnormal liver function tests, and anemia.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Any bleeding (21.7%), clinically-relevant non-major bleeding (up to 18.1%)</p>
<p><b>Common</b> (1% to 10%): Major bleeding, anemia-related adverse events, non-fatal non-critical organ bleeding, clinically relevant bleeding, anemia</p>
<p><b>Uncommon</b> (0.1% to 1%): Fatal bleeding, non-fatal critical organ bleeding, a 2 g/dL or greater decrease in hemoglobin, blood loss requiring transfusion of 2 or more units of RBC, thrombocytopenia</p>
<p><b>Rare</b> (less than 0.1%): Fatal non-intracranial bleeding<sup>[Ref]</sup></p><p>Major bleeding included intracranial hemorrhage (ICH), gastrointestinal hemorrhage, and fatal bleeds.  A major bleeding event was defined as clinically overt bleeding that met one of the following criteria: fatal bleeding, symptomatic bleeding in a critical site (e.g.  spine, eye), drop in hemoglobin of at least 2 g/dL, or a drop in hematocrit of at least 6%.  A clinically relevant non-major bleed was defined as overt bleeding that required medical intervention.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Major GI bleeds included both upper and lower GI bleeds.  A GUSTO severe GI bleed is defined as a severe or life-threatening bleed that causes hemodynamic compromise and requires intervention.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Major gastrointestinal (GI) bleeding, upper GI bleeding, lower GI bleeding (including anorectal bleeding), oral and pharyngeal bleeding, abdominal pain, nausea</p>
<p><b>Uncommon</b> (0.1% to 1%): GUSTO severe GI bleeding</p>
<p><b>Rare</b> (less than 0.1%): Fatal GI bleed, retroperitoneal hemorrhage<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Dizziness, headache</p>
<p><b>Uncommon</b> (0.1% to 1%): Any intracranial hemorrhage (ICH), hemorrhagic stroke, ICH other than hemorrhagic stroke, fatal ICH<sup>[Ref]</sup></p><p>ICH included hemorrhagic stroke, subarachnoid hemorrhage, epidural/subdural hemorrhage, and ischemic stroke with major hemorrhage.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Vaginal bleeding, macroscopic hematuria, urethral bleeding<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Cutaneous soft tissue bleeding, rash, pruritus</p>
<p><b>Uncommon</b> (0.1% to 1%): Urticaria<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Abnormal liver function tests, blood bilirubin increased, gamma-glutamyltransferase increased</p>
<p><b>Uncommon</b> (0.1% to 1%): Blood alkaline phosphatase increased, transaminases increased<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Epistaxis</p>
<p><b>Uncommon</b> (0.1% to 1%): Interstitial lung disease (ILD), hemoptysis<sup>[Ref]</sup></p><p>Most cases of ILD were confounded by concurrent amiodarone, which is known to cause ILD, or infectious pneumonia.  Overall, 5 patients out of 5417 died of ILD during the course of the study.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Puncture site bleeding</p>
<p><b>Uncommon</b> (0.1% to 1%): Surgical site hemorrhage</p>
<p><b>Rare</b> (less than 0.1%): Procedural hemorrhage<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity</p>
<p><b>Rare</b> (less than 0.1%): Anaphylactic reaction, allergic edema<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Conjunctival/scleral hemorrhage, intraocular hemorrhage<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Rare</b> (less than 0.1%): Intramuscular hemorrhage (no compartment syndrome), intra-articular hemorrhage</p>
<p><b>Frequency not reported</b>: Compartment syndrome<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Rare</b> (less than 0.1%): Pericardial hemorrhage</p>
<p><b>Frequency not reported</b>: Hypoperfusion<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Renal failure<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc., Parsippany, NJ. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about edoxaban</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>3 Reviews</li>
<li>Drug class: factor Xa inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Edoxaban &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Savaysa</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Atrial Fibrillation</li>
<li>Deep Vein Thrombosis</li>
<li>Prevention of Thromboembolism in Atrial Fibrillation</li>
<li>Pulmonary Embolism</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to edoxaban: oral tablet</i></p><h3>General</h3><p>During nonvalvular atrial fibrillation treatment, the most common adverse reactions were bleeding and anemia.  During deep venous thromboembolism and pulmonary embolism treatment, the most common adverse reactions were bleeding, rash, abnormal liver function tests, and anemia.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Any bleeding (21.7%), clinically-relevant non-major bleeding (up to 18.1%)</p><p><b>Common</b> (1% to 10%): Major bleeding, anemia-related adverse events, non-fatal non-critical organ bleeding, clinically relevant bleeding, anemia</p><p><b>Uncommon</b> (0.1% to 1%): Fatal bleeding, non-fatal critical organ bleeding, a 2 g/dL or greater decrease in hemoglobin, blood loss requiring transfusion of 2 or more units of RBC, thrombocytopenia</p><p><b>Rare</b> (less than 0.1%): Fatal non-intracranial bleeding<sup>[Ref]</sup></p><p>Major bleeding included intracranial hemorrhage (ICH), gastrointestinal hemorrhage, and fatal bleeds.  A major bleeding event was defined as clinically overt bleeding that met one of the following criteria: fatal bleeding, symptomatic bleeding in a critical site (e.g.  spine, eye), drop in hemoglobin of at least 2 g/dL, or a drop in hematocrit of at least 6%.  A clinically relevant non-major bleed was defined as overt bleeding that required medical intervention.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Major GI bleeds included both upper and lower GI bleeds.  A GUSTO severe GI bleed is defined as a severe or life-threatening bleed that causes hemodynamic compromise and requires intervention.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Major gastrointestinal (GI) bleeding, upper GI bleeding, lower GI bleeding (including anorectal bleeding), oral and pharyngeal bleeding, abdominal pain, nausea</p><p><b>Uncommon</b> (0.1% to 1%): GUSTO severe GI bleeding</p><p><b>Rare</b> (less than 0.1%): Fatal GI bleed, retroperitoneal hemorrhage<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Dizziness, headache</p><p><b>Uncommon</b> (0.1% to 1%): Any intracranial hemorrhage (ICH), hemorrhagic stroke, ICH other than hemorrhagic stroke, fatal ICH<sup>[Ref]</sup></p><p>ICH included hemorrhagic stroke, subarachnoid hemorrhage, epidural/subdural hemorrhage, and ischemic stroke with major hemorrhage.<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Vaginal bleeding, macroscopic hematuria, urethral bleeding<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Cutaneous soft tissue bleeding, rash, pruritus</p><p><b>Uncommon</b> (0.1% to 1%): Urticaria<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Abnormal liver function tests, blood bilirubin increased, gamma-glutamyltransferase increased</p><p><b>Uncommon</b> (0.1% to 1%): Blood alkaline phosphatase increased, transaminases increased<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Epistaxis</p><p><b>Uncommon</b> (0.1% to 1%): Interstitial lung disease (ILD), hemoptysis<sup>[Ref]</sup></p><p>Most cases of ILD were confounded by concurrent amiodarone, which is known to cause ILD, or infectious pneumonia.  Overall, 5 patients out of 5417 died of ILD during the course of the study.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Puncture site bleeding</p><p><b>Uncommon</b> (0.1% to 1%): Surgical site hemorrhage</p><p><b>Rare</b> (less than 0.1%): Procedural hemorrhage<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity</p><p><b>Rare</b> (less than 0.1%): Anaphylactic reaction, allergic edema<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Conjunctival/scleral hemorrhage, intraocular hemorrhage<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Rare</b> (less than 0.1%): Intramuscular hemorrhage (no compartment syndrome), intra-articular hemorrhage</p><p><b>Frequency not reported</b>: Compartment syndrome<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Rare</b> (less than 0.1%): Pericardial hemorrhage</p><p><b>Frequency not reported</b>: Hypoperfusion<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Renal failure<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Savaysa (edoxaban)." Daiichi Sankyo, Inc., Parsippany, NJ. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2>More about edoxaban</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>3 Reviews</li>
<li>Drug class: factor Xa inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Edoxaban &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Atrial Fibrillation</li>
<li>Deep Vein Thrombosis</li>
<li>Prevention of Thromboembolism in Atrial Fibrillation</li>
<li>Pulmonary Embolism</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>